Christine Rothe | Chief Development Officer
iOmx Therapeutics AG

Christine Rothe, Chief Development Officer, iOmx Therapeutics AG

Christine Rothe serves as Chief Development Officer at iOmx Therapeutics where she is responsible for research and development programs. Christine has a long-standing track record in discovery and development of drug candidates. Before joining iOmx, Christine held positions of increasing responsibility in R&D and Alliance Management at Pieris Pharmaceuticals and MorphoSys AG. At Pieris, Christine played a major role in shaping the drug discovery process and bringing bispecifics in immuno-oncology from the start of the program into the clinic. Christine started her industry career at MorphoSys leading technology development as well as therapeutic antibody projects.

Appearances:



Festival of Biologics Day 2 @ 15:00

IOMX-0675 - A Differentiated and Highly Potent LILRB1 and LILRB2 Targeting Antibody

  • LILRB1 and LILRB2 play an important role in modulating the immunosuppressive tumor microenvironment in solid tumors while LILRA1 and LILRA3 are closely related immune-activating family members
  • We applied our proprietary phage display library to select IOMX-0675, a fully human antibody, clearly differentiating between LILRB1/2 and LILRA1/3 
  • The unique binding profile translates into high efficacy positioning IOMX-0675 as a dual-targeting checkpoint inhibitor with best-in-class potential.  
  • Recent CTA approval enables preparing for a FIH study
last published: 01/Aug/25 16:05 GMT

back to speakers

Get involved at Festival of Biologics Basel 2025

 

 

TO SPONSOR


Derek Cavanagh

[email protected]

 

Jack Bebb
[email protected]

 

TO SPEAK


Jack Beard
[email protected]

 

MARKETING & PRESS


Ollie McDaid

[email protected]

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.